Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated HIV-1 Infected Controllers

Key Inclusion Criteria:

- Plasma HIV-1 RNA levels <50 copies/mL at screening

- Chronic HIV-1 infection (for ≥ 6 months) prior to ART initiation

- Pre-ART Plasma HIV-1 RNA set point between 50 and ≤ 5,000 copies/mL measured within
two years prior to ART initiation

- On ART for ≥ 6 months prior to screening

- Documented plasma HIV-1 RNA < 50 copies/mL for ≥ 6 months preceding the screening
visit (or undetectable HIV-1 RNA level according to the local assay being used if the
limit of detection is ≥ 50 copies/mL). Unconfirmed virologic elevations of ≥ 50
copies/mL (transient detectable viremia, or "blip") prior to screening are acceptable.

- No documented history of resistance to any components of the current ART regimen

- Availability of a fully active alternative ART regimen, in the opinion of the
Investigator, in the event of discontinuation of the current ART regimen with
development of resistance.

- Hemoglobin ≥ 11.5 g/dL (males) or ≥ 11 g/dL (females)

- White Blood Cells ≥ 2,500 cells/μL

- Platelets ≥ 125,000/mL

- Absolute Neutrophil Counts ≥ 1000 cells/μL

- CD4+ count ≥ 500 cells/μL

- Alanine aminotransferase (ALT), aspartate aminotransferase (AST) or bilirubin ≤ 2 ×
upper limit of normal (ULN)

- Estimated glomerular filtration rate ≥ 60 mL/min

- No autoimmune disease requiring on-going immunosuppression

- No evidence of current hepatitis B virus (HBV) infection

- No evidence of current hepatitis C virus (HCV) infection (positive anti-HCV antibody
and negative HCV polymerase chain reaction (PCR) results are acceptable)

- No documented history of pre-ART CD4 nadir < 200 cells/μL (unknown pre-ART CD4 nadir
is acceptable)

- No history of opportunistic illness indicative of stage 3 HIV

- No acute febrile illness within 35 days prior to Pre-Baseline/ Day -13

Note: Other protocol defined Inclusion/Exclusion criteria may apply.